AstraZeneca is the latest pharma company enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC.
- MHRA Class 2 medicine recalls – May/June 2025 June 13, 2025
- Lancet study illustrates drug delivery “milestone” June 12, 2025
- FDA grants expanded approval for hepatitis drug June 11, 2025
- Construction begins on new WuXi microbial manufacturing site June 10, 2025
- Multi-billion-pound funding to accelerate UK’s high-growth sectors June 9, 2025
- Duchenne gene therapy interim trial outcomes “striking” June 6, 2025
- Third Circuit Holds That Granting Discovery Under Section 1782 Is Not a “Final” Judgment June 13, 2025
- Sandoz Launches PYZCHIVA® (Ustekinumab) Autoinjector in Europe June 4, 2025
- Samsung Bioepis Secures Marketing Approval in Korea for its Biosimilar to Amgen’s Bone Cancer Drug Xgeva June 3, 2025
- EMA Issues Positive CHMP Opinions for Fresenius Denosumab Biosimilars June 2, 2025
- Celltrion, Samsung Bioepis, and Organon Receive Interchangeability Designations for Adalimumab Biosimilars June 2, 2025
- Starting with the End in Mind: How Pharma Can Build a Smarter Path to Commercialization June 13, 2025
- The 340B Contract Pharmacy Market in 2025: Big Chains and PBMs Tighten Their Grip June 10, 2025
- Moving Beyond Mitigation: Cracking the Maximizer Code to Protect Patient Affordability June 6, 2025
- Pharmacist Salaries and Employment in 2024: Retail Employment Collapse Offset by Hospital Boom June 3, 2025
- Three Ways GoodRx Is Helping Pharmacies Increase Profitability and Drive Innovation May 30, 2025
- Drug Channels News Roundup, May 2025: MFN Controversy, Plan Sponsors ♥️ Rebates, PBM Profits, and Fun in Congress May 28, 2025
- How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs May 21, 2025